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At a glance commentary: 57	
Ivacaftor restores cystic fibrosis transmembrane conductance regulator (CFTR) function in 58	
people with cystic fibrosis and a gating mutation. Treatment is associated with improved 59	
lung function, increased weight and reduced exacerbation frequency. The question now 60	
arises as to whether some of the long-term treatments recommended to people with CF are 61	
needed in those who remain clinically stable whilst receiving ivacaftor. In-vitro data suggests 62	
ivacaftor may have bactericidal properties, however the long-term impact of CFTR 63	
restoration on chronic respiratory infection is unknown and greater understanding is vital to 64	
addressing the on-going need for chronic anti-infective therapies in this population. 65	
 66	
This study includes the longest follow-up of respiratory infection in people receiving 67	
ivacaftor and provides evidence of sustained reductions in infection important CF 68	
pathogens. For the first time we have shown that lower post-ivacaftor P. aeruginosa 69	
prevalence appear to be driven by a combination of reduced acquisition and increased 70	
clearance of infection. These findings have important implications for antibiotic stewardship 71	
in people receiving ivacaftor. 72	
 73	
Online Data Supplement: This article has an online data supplement, which is accessible 74	
from the issue’s table of content online at www.atsjournals.org  75	
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Abstract 78	
Rationale:  79	
Ivacaftor can greatly improve clinical outcomes in people with cystic fibrosis (CF) and has 80	
been shown to have in-vitro antibacterial properties, yet the long-term microbiological 81	
outcomes of treatment are unknown. 82	
Objectives:  83	
To investigate changes in respiratory microbiology associated with long-term ivacaftor use. 84	
Methods:  85	
Retrospective cohort study utilising data from the United Kingdom CF Registry 2011-2016. 86	
Primary outcome was the annual prevalence ratios for key CF pathogens between ivacaftor 87	
users and their contemporaneous comparators. Multivariable log-binomial regression 88	
models were designed to adjust for confounders. Changes in Pseudomonas aeruginosa 89	
status were compared between groups using non-parametric maximum likelihood estimate 90	
for the purposes of Kaplan-Meier approximation.   91	
Results 92	
Ivacaftor use was associated with early and sustained reduction in P. aeruginosa rates (2016 93	
Adjusted Prevalence Ratio [95% CI] 0.68 [0.58, 0.79], p<0.001) via a combination of 94	
increased clearance in those with infection (Ivacaftor: 33/87 [37.9%] vs. Non ivacaftor: 95	
432/1872 [22.8%], p<0.001) and reduced acquisition in those without infection (49/134 96	
[36.6%] vs. 1157/2382 [48.6%], p=0.01). The improved prevalence of P. aeruginosa infection 97	
was independent of reduced sampling in the ivacaftor cohort. Ivacaftor was also associated 98	
with reduced prevalence of Staphylococcus aureus and Aspergillus spp. but not Burkholderia 99	
cepacia complex. 100	
Conclusion 101	
In this study, long-term ivacaftor use was associated with reduced infection with important 102	
CF pathogens including P. aeruginosa. These findings have implications for antibiotic 103	
stewardship and the need for on-going chronic antimicrobial therapy in this cohort.   104	
  105	
 106	
Introduction: 107	
Cystic fibrosis (CF) is an ion-transport disease caused by mutations in the gene encoding for 108	
the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Dehydrated, viscid 109	
epithelial secretions result in a cycle of stasis, infection and inflammation in multiple organ 110	
systems but manifest most obviously in the lungs where chronic infection results in a 111	
progressive and irreversible decline in pulmonary function.  112	
 113	
Recently, therapies aimed at correcting the underlying CFTR defect have become available 114	
and ivacaftor (Vertex Pharmaceuticals, USA), a CFTR potentiator, can restore CFTR function 115	
in people with a gating mutation such as G551D. Available in the UK since 2013, improved 116	
lung function, increased weight, reduced sweat chloride and improved exacerbation 117	
frequency have been demonstrated in short and long-term studies. (1, 2)  118	
 119	
Chronic infection with classical CF pathogens such as Pseudomonas aeruginosa often 120	
requires long-term suppressive antibiotic therapy, which imparts a significant treatment 121	
burden on people with CF and also has implications for anti-microbial resistance (AMR).	 (3, 122	
4)  Ivacaftor may influence these respiratory pathogens and potentially reduce the need for 123	
such aggressive antibiotic therapy through two mechanisms.  Firstly, the presence of a 124	
quinolone ring in its chemical structure may confer antibiotic properties and direct 125	
bactericidal activity has been confirmed in-vitro, where a potential synergism with 126	
colistimethate has been reported. (5-8) Secondly, correction of CFTR activity by ivacaftor 127	
may restore ion flux such that changes in the pulmonary microenvironment can influence 128	
the ability of bacteria to survive in that niche.   As some people with CF remain clinically 129	
stable having received over 5 years of ivacaftor therapy, understanding the long-term 130	
microbiological consequences becomes increasingly important for predicting future 131	
morbidity and also in implementing antibiotic stewardship.   132	
 133	
The objective of this study was therefore to investigate the long-term microbiological 134	
outcomes associated with the use of ivacaftor. 135	
Methods: 136	
Study design 137	
We undertook a retrospective cohort study utilising data from the UK CF Registry for the 138	
period 2011-2016. The UK CF Registry Steering Committee approved the study. The UK CF 139	
Registry is a Research Ethics Committee approved (Huntingdon Research Ethics Committee 140	
07/Q0104/2) database holding demographic, clinical care, medication and health outcome 141	
data with excellent coverage of the CF population. The UK CF Registry data includes the 142	
annual presence or absence of key CF pathogens in respiratory cultures for each subject. For 143	
2016, additional data including the number of respiratory cultures and number positive for 144	
P. aeruginosa were available.  145	
Population 146	
People with CF aged 6 and under were excluded from the study due to lack of consistent 147	
lung function and microbiology data.  All individuals with at least one documented G551D 148	
mutation, who started ivacaftor treatment in 2013, were still receiving ivacaftor in 2016 and 149	
had complete microbiology data (a recorded status for each pathogen of interest for each 150	
year), formed the treatment cohort. The rest of the CF population formed the non-ivacaftor 151	
comparator group. Subjects were excluded from the comparator cohort if they had received 152	
ivacaftor at any point since 2013 or if they had incomplete microbiology data for the study 153	
period.  154	
Outcomes 155	
The outcomes of primary interest were the annual prevalence ratios for each CF pathogen. 156	
Secondary outcomes included time to P. aeruginosa infection in those previously 157	
uninfected, and vice versa: time to P. aeruginosa clearance in those previously infected. 158	
Primary outcome analysis and adjustment 159	
Prevalence of a positive respiratory culture for P. aeruginosa, Staphylococcus aureus, 160	
Aspergillus spp. and the Burkholderia cepacia complex (BCC) were calculated annually 2011-161	
2016. The two years preceding ivacaftor initiation in 2013 were included to allow more 162	
robust comparison of pre-ivacaftor microbiological trajectories.  Annual prevalence ratios 163	
were calculated using two approaches. Firstly, the unadjusted ratio between the annual 164	
prevalence of each pathogen in the treatment and comparator cohorts. Secondly, a log-165	
binomial regression model adjusted for known confounders identified from a review of the 166	
literature, see Supplement. Visual representation of identified potential associations in a 167	
direct acyclic graph was used to identify variables that were confounders, but not mediators 168	
or colliders, for inclusion in the model.  Results from both unadjusted and adjusted analyses 169	
are presented as prevalence ratios with 95% confidence intervals. 170	
Acquisition and clearance analyses 171	
To assess whether changes in P. aeruginosa prevalence in the ivacaftor cohort were driven 172	
predominantly by changes in clearance, acquisition or a combination of the two, we 173	
classified any individual with positive respiratory cultures in each of the two years prior to 174	
ivacaftor initiation in 2013 as “infected” and any subject with no positive respiratory 175	
cultures in that period as “uninfected”. Acquisition was defined as any member of the 176	
“uninfected” group with a subsequent positive respiratory culture. Clearance was defined as 177	
any member of the “infected” group without a recorded positive respiratory culture in any 178	
subsequent year. Given the precise timepoints for clearance and acquisition were known 179	
only within a defined 12-month period, we treated events as interval-censored data and 180	
calculated the non-parametric maximum likelihood estimate for the purposes of Kaplan-181	
Meier approximation. (9)  182	
Sensitivity analyses 183	
To address the robustness of our primary analysis we performed a number of further 184	
analyses.  Quantitative sample data, i.e. number of respiratory samples per year, was only 185	
available for the year 2016 and consequently could not be included in the analysis 186	
throughout. To test the impact of this variable on effect estimates we performed two 187	
sensitivity analyses by firstly including total sputum samples in a regression model for 2016 188	
data and secondly, a restricted analysis, where all subjects providing < 3 sputum samples in 189	
2016 were excluded. Given an in-vitro synergism between colistimethate and ivacaftor has 190	
been reported, (8) we performed a separate second restriction analysis excluding those 191	
receiving inhaled colistimethate preparations at any stage during the study period. 192	
Statistical analyses 193	
All analyses were performed in R (v3.3.3, R Foundation for Statistical Computing, 2018). 194	
Summary statistics including counts and percentages for categorical variables and means 195	
and standard deviations for continuous variables were used to describe the study cohorts. 196	
Between-group comparisons were made using t-tests or Mann-Whitney test for parametric 197	
and non-parametric continuous data respectively, with Chi-square test used for categorical 198	
data. Unadjusted p-values are presented throughout with statistical significance considered 199	
<0.05. 200	
Results: 201	
Study cohort 202	
In 2013, 276 people with CF and at least one G551D mutation met the inclusion criteria for 203	
the ivacaftor group and 5296 were included in the non-ivacaftor comparator group, see 204	
Supplement: Figure S1). Baseline characteristics of both groups for the year 2012 are 205	
presented in Table 1. 206	
Reduced prevalence of CF pathogens following ivacaftor initiation  207	
In 2012 the ivacaftor cohort had similar P. aeruginosa prevalence as their matched 208	
comparators (128/276, 46.4% vs. 2536/5296, 47.9%), see Table 2, however following 209	
ivacaftor initiation in 2013 the annual prevalence of P. aeruginosa fell in the ivacaftor cohort 210	
(48.9%, 40.6%, 37.0% and 35.9% for 2013-2016 respectively), see Figure 1. Smaller 211	
reductions were observed for S. aureus (prevalence 33.3%, 30.1%, 25.7%, and 30.1% for 212	
2013-2016 respectively). From 2013 to 2016, Aspergillus spp. prevalence in the ivacaftor 213	
cohort fell from 12.0% to 4.7%, but for the same time-period there was <1% change in BCC 214	
prevalence in both cohorts, see Table 2.  215	
Primary outcome  216	
Prevalence ratios for a positive culture between the ivacaftor group and their matched 217	
comparators were calculated and are presented in Figure 2 & Table 2. In 2014 ivacaftor use 218	
was associated with reduced rate of positive culture for P. aeruginosa (Adjusted PR [95% CI] 219	
0.78 [0.68, 0.89], p<0.001) and Aspergillus spp. (Adjusted PR 0.56 [0.40, 0.77], p<0.001), 220	
however estimates were smaller for S. aureus (Adjusted PR 0.92 [0.76, 1.1], p=0.39), see 221	
Table 2.  Prevalence ratio for P. aeruginosa continued to decrease throughout the study 222	
period such that by 2016 there was a 32% reduction (Adjusted PR 0.68 [0.58, 0.79], 223	
p<0.001). After three years of treatment, less pronounced changes were observed for S. 224	
aureus (Adjusted PR 0.85 [0.70, 1.01], p=0.08). 225	
  226	
Independence of improved P. aeruginosa rates from reductions in sampling. 227	
In 2016 there were quantitative data available for the number of respiratory cultures 228	
performed. The ivacaftor group had fewer sputum samples in that year than their 229	
comparators (median [IQR]: 2 [0-6] vs. 4 [1-7], p<0.001) but similar total annual cough-230	
swabs. The association between ivacaftor use and reduced P. aeruginosa remained when 231	
sputum sample count was included into the multivariable model for 2016, see Table S1. 232	
Furthermore, a restricted analysis including only “sputum producers” (those individuals with 233	
≥3 sputum samples) found results consistent with the primary analysis, see Figure S3. 234	
Combination of increased clearance and reduced acquisition contribute to improved P. 235	
aeruginosa rates. 236	
Next we investigated whether reduced acquisition, increased clearance or both drove the 237	
changes in P. aeruginosa prevalence. In those individuals with 2 years of documented P. 238	
aeruginosa growth prior to 2013, there were significantly higher rates of clearance in the 239	
ivacaftor group by the end of the study period (33/87 [37.9%] vs. 432/1872 [22.8%], 240	
p<0.001), Figure 3a. Furthermore, in those subjects without P. aeruginosa growth in the 2 241	
years prior to 2013, fewer subjects receiving ivacaftor had a subsequent growths (49/134 242	
[36.6%] vs. 1157/2382 [48.6%], p=0.01), Figure 3b.  243	
 244	
Characteristics of individuals with change in P. aeruginosa status 245	
Next we tested the hypothesis that subjects with a change in P. aeruginosa infection status 246	
following ivacaftor initiation may have different clinical characteristics to those who did not. 247	
Those who cleared P. aeruginosa whilst receiving ivacaftor were younger (25.1 ± 8.8 years 248	
vs. 29.0 ± 8.3 years, p=0.03) and had a greater sweat chloride responses 6-8 weeks post-249	
ivacaftor initiation, see Table 3. Those who acquired P. aeruginosa whilst receiving ivacaftor 250	
had poorer lung function at baseline (FEV1 80.9 ± 20.4 % predicted vs. 90.1 ± 18.1 % 251	
predicted, p=0.005), but no other significant differences, see Table 4.  252	
Antibiotic usage 253	
We compared antibiotic treatments between each group at baseline and across the study 254	
period. Rates of anti-pseudomonal antibiotic usage were similar at baseline see Table 1. 255	
Median years receiving inhaled antibiotics was also similar between groups (median [IQR] 2 256	
years [1-4] vs. 3 years [1-4], p=0.40), and in no year was inhaled antibiotic use significantly 257	
greater in the ivacaftor group, Figure S4. Finally, in an analysis restricted only to those who 258	
did not receive inhaled colistimethate during the study period, we found our primary 259	
analysis was robust, suggesting the previously reported in-vitro synergism between ivacaftor 260	
and colistimethate was not acting as a confounder, see Figure S5. (8) 261	
 262	
Discussion: 263	
We used longitudinal data from the UK CF Registry to investigate changes in sputum 264	
microbiology associated with ivacaftor use in people with CF aged six years and above. 265	
Ivacaftor use was associated with early and sustained reductions in positive respiratory 266	
cultures for P. aeruginosa such that the likelihood of a positive culture was reduced by 32% 267	
after three years of treatment. This association persisted even when adjusted for the 268	
reduced sampling seen in those receiving ivacaftor. These findings have implications for the 269	
need for ongoing chronic suppressive antimicrobial therapy in those receiving ivacaftor. 270	
Significant reductions in S. aureus were also observed, but only from the second year of 271	
treatment onwards and absolute reductions in prevalence were smaller than for P. 272	
aeruginosa. Early reductions in Aspergillus spp. were also observed, however the relatively 273	
low frequency in the ivacaftor group means this finding must be interpreted with caution. 274	
No association with BCC infection was observed although given the low prevalence of BCC 275	
infection, our study is likely underpowered in this regard. 276	
 277	
The reductions in P. aeruginosa seen here are in keeping with previous smaller studies, 278	
where the odds of a positive culture were reduced in the year following ivacaftor initiation. 279	
(10-12) We found reduced S. aureus following ivacaftor initiation, a finding also reported by 280	
a French study of 2 years ivacaftor experience but not observed in the G551D Observational 281	
(GOAL) Study, a prospective observational study in the US which reported culture results 282	
after one year of ivacaftor treatment. (10, 12) Here, differences to the GOAL study may be 283	
partly explained by the much larger cohort and longer follow up period in our study, 284	
particularly as significant reductions in S. aureus culture positivity only occurred in the latter 285	
two years of our follow-up period. (10) The GOAL study lacked a comparator group and our 286	
use of the UK CF Registry allowed us to confirm changes were limited to those receiving 287	
ivacaftor rather than in the wider CF population. Furthermore, GOAL was a US study and 288	
comparisons between different countries and healthcare systems are challenging, 289	
particularly given Bessanova et al (13) recently reported reduced S. aureus in people 290	
receiving ivacaftor in the US but not in the UK, where baseline S. aureus prevalence was half 291	
of that in the US. The same study found similar reductions in P. aeruginosa and Aspergillus 292	
spp. as seen here but only included one year of follow up. We were able to include the three 293	
years post-ivacaftor initiation, the largest follow up of microbiological outcomes in this 294	
discrete patient group to date. The large dataset and longer follow up allowed us to show, 295	
for the first time, that changes in P. aeruginosa sputum positivity appear to be driven both 296	
by increased clearance and also reduced acquisition.  297	
 298	
The question arises as to why ivacaftor is associated with a pronounced effect against P. 299	
aeruginosa in the CF lung. Although the quinolone ring in its chemical structure may confer 300	
innate antibacterial properties, in-vitro studies have demonstrated most activity against 301	
Gram-positive organisms such as S. aureus rather than P. aeruginosa, although when used in 302	
combination with colistimethate a synergistic effect against P. aeruginosa has been 303	
reported. (5-7) We found earlier and larger reductions in P. aeruginosa, regardless of 304	
colistimethate use, suggesting a direct bactericidal effect from ivacaftor is not the 305	
predominant mechanism for the changes we observed. Furthermore, clearance of P. 306	
aeruginosa was associated with a greater sweat chloride response to ivacaftor and any 307	
antimicrobial effect seems more likely related directly to CFTR restoration.  308	
 309	
CFTR restoration has been associated with improved mucociliary clearance, which could 310	
explain some of the changes we observed. (14) However, increased elimination of bacteria 311	
by this mechanism should be species agnostic and might even favour elimination of species 312	
such as S. aureus that do not form biofilms as readily, we found the opposite. Alternatively, 313	
restoration of CFTR function has recently been associated with increased airway surface 314	
liquid pH, mirroring changes within the gut where pH normalised following ivacaftor 315	
initiation, and this may restore activity of some pH dependent innate antimicrobial 316	
peptides. (14-16) Equally, such changes to regional growth conditions could 317	
disproportionately affect P. aeruginosa since it is well adapted to the CFTR-defective lung, 318	
where it gains a selective advantage via a number of complex physiological changes driven 319	
by mutations resulting in different genotypic and phenotypic traits. (17, 18) Whilst these 320	
traits allow it to successfully establish chronic infection, rapid and dramatic restoration of 321	
CFTR function could potentially render it vulnerable in an environment it is no longer 322	
adapted to survive. In keeping with this, ivacaftor initiation has previously been implicated 323	
in reductions of mucoid but not non-mucoid P. aeruginosa. (11) Finally, functional CFTR 324	
plays a specific role in the innate immune response to P. aeruginosa and hence ivacaftor 325	
may exert influence on P. aeruginosa by restoring that function. (19, 20) Interestingly, CFTR 326	
has also been implicated in the immune response to Aspergillus spp., for which we also 327	
found reductions following ivacaftor initiation. (21) 328	
 329	
Our findings of reduced CF pathogens are relevant clinically given the morbidity associated 330	
with chronic infection by these species (22-24), and imply there may be potential to safely 331	
reduce the treatment burden in some patients. Indeed, one third of individuals with chronic 332	
P. aeruginosa infection prior to ivacaftor initiation were culture negative at the end of the 333	
study period. We found that older people with CF were less likely to eradicate pathogens, a 334	
finding supported by a smaller study by Hisert et al (25) of older adults with CF. In that 335	
study, although clearance of P. aeruginosa was not observed, bacterial load was initially 336	
reduced following ivacaftor initiation yet increased in the second year of treatment and the 337	
authors speculated that P. aeruginosa could diversify to survive in a CFTR restored 338	
environment, suggesting an on-going need for anti-pseudomonal therapies in those who 339	
remain culture positive.  340	
 341	
Addressing selection bias and confounding in observational studies of drug effects is 342	
inherently challenging. We used a multivariable log-binomial regression model to adjust for 343	
known confounders but there remains potential for residual confounding particularly with 344	
respect to unmeasured imbalance between groups. Misclassification is an inherent risk in 345	
registry based studies, and in attempt to mitigate this we only included individuals with two 346	
consecutive years of a similar microbiological status in our clearance and acquisition 347	
analyses. Since we excluded those under the age of 6 and those with incomplete 348	
microbiological data, including those who died during the study period, our findings may not 349	
be generalisable to young children and those with more severe disease. Equally, a larger 350	
proportion of patients were excluded from the potential comparator group than the 351	
ivacaftor group due to insufficient data (most likely due to continued ivacaftor prescription 352	
being dependent on regular follow up) and thus we cannot exclude a sampling bias in that 353	
cohort. Given the registry based nature of this study there is also a risk of bias from inter-354	
centre variation. For example respiratory culture sampling, processing and laboratory 355	
assessment may differ between centres particularly with regard low volume, or low quality 356	
specimens.  357	
 358	
There is a risk of indication bias in that ivacaftor use is dictated by genotype, where some 359	
are associated with increased bacterial colonisation. (26) However, groups had similar rates 360	
of class I-III mutations and, importantly, had comparable sputum microbiology in both pre-361	
ivacaftor years suggesting they were on similar microbiological trajectories. With regards to 362	
microbiology, for most of the study period the UK CF Registry recorded only the presence or 363	
absence of each pathogen in that year, hence for the most part we are unable to determine 364	
if the proportion of positive samples changed over time. Quantitative data for P. aeruginosa 365	
was available for 2016, which allowed us to confirm the changes we observed were 366	
consistent even when adjusted for reduced sampling in the ivacaftor group. 367	
 368	
The strengths of this study lie in the large sample size and the longest follow-up period to 369	
date. The large dataset afforded us by utilising the UK CF registry allowed us to demonstrate 370	
for the first time that both increased clearance and reduced acquisition contributed to 371	
reductions in P. aeruginosa infection following ivacaftor initiation. 372	
 373	
Conclusion 374	
In summary, we utilised national registry data to compare changes in respiratory 375	
microbiology in the years after ivacaftor initiation. We found ivacaftor was associated with 376	
reductions in lung infections by important CF pathogens.   377	
 378	
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  479	
 480	
Figure 1:  Annual prevalence (± 95% confidence interval) of a positive 481	
respiratory culture for P. aeruginosa (A), S. aureus (B), Aspergillus spp. (C), B. 482	
cepacia complex (D) in the ivacaftor (n=276) and non-ivacaftor groups 483	
(n=5296). Dotted black line represents ivacaftor initiation in 2013. 484	
 485	
 486	
Figure 2:  Adjusted prevalence ratio ± 95% confidence intervals between the 487	
ivacaftor (n=276) and non-ivacaftor users (5296)  for a positive respiratory 488	
culture  for P. aeruginosa (A), S. aureus (B), Aspergillus spp. (C), B. cepacia 489	
complex (D).  490	
 491	
 492	
Figure 3:  Kaplan-meier curve for clearance of P. aeruginosa infection in 493	
previously infected individuals (A) and acquisition of P. aeruginosa infection in 494	
previously uninfected individuals (B).  495	
  496	
  497	
Table 1: Baseline characteristics of included subjects (n=5572) by ivacaftor use. 498	
Data are taken from year 2012, the year prior to ivacaftor initiation, and are 499	
presented as count (%) and mean (SD). 500	
 501	
 502	
 503	
 504	
Abbreviations: CFRD= Cystic fibrosis related diabetes; FEV1= Forced expiratory volume in 1 505	
second; IV= intravenous 506	
  507	
 Ivacaftor Non-ivacaftor 
n 276  5296  
Age 21.43 (10.4) 23.4 (12.0) 
Male 154 (55.8) 2815 (53.2) 
CFRD 47 (17) 1281 (24.2) 
Pancreatic enzymes 255 (92.4) 4538 (86.5) 
FEV1,  predicted 81.07 (22.5) 72.91 (23.3) 
FEV1, litres 2.5 (1.0) 2.16 (1.01) 
Body mass index    
Adults, kg/m2 23.17 (3.4) 22.47 (3.76) 
Children, percentile 55.48 (26.8) 48.34 (28.5) 
Annual IV days 13.14 (20.8) 19.56 (28.9) 
Microbiology    
P. aeruginosa 128 (46.4) 2536 (47.9) 
Chronic 102 (37.0) 2068 (39.0) 
S. aureus 89 (32.2) 1489 (28.1) 
Chronic 58 (21) 996 (18.8) 
B. cenocepacia 4 (1.4) 48 (0.9) 
B. multivorans 3 (1.1) 100 (1.9) 
Aspergillus spp. 34 (12.3) 733 (13.8) 
Genotype    
Class I-III 232 (84.1) 3977 (75.1) 
Phe508del homozygous 2 (0.7) 2881 (54.4) 
Phe508del heterozygous 200 (72.5) 1783 (33.7) 
Nebulised anti-pseudomonal   
Any 135 (48.9) 2401 (45.3) 
Tobramycin 67 (24.3) 1200 (22.7) 
Colistimethate 103 (37.3) 1793 (33.9) 
Oral Macrolide 139 (50.4) 2505 (47.3) 
Table 2: Annual prevalence of P. aeruginosa, S. aureus, Aspergillus spp. And 508	
BCC in ivacaftor (n=276) and non-ivacaftor (n=5296) users. Unadjusted and 509	
adjusteda prevalence ratios are presented with 95% confidence intervals. 510	
a: Multivariable log- binomial regression model adjusted for age and genotype.  511	
 512	
 513	
Table 3: Clinical characteristics of individuals with two years of consecutive P. 514	
aeruginosa growth with comparison based upon subsequent clearance. Data 515	
are presented as mean (SD) or count (%). 516	
P. aeruginosa 
         
  
Ivacaftor 
 
Non-ivacaftor Unadjusted Prevalence Ratio 
 
Adjusted Prevalence Ratio 
Year 
 
Culture-
positive (%) 
Culture-positive 
(%) 
PR [95% CI] p 
 
PR [95% CI] p 
2011 
 
101 (36.6) 
 
2250 (42.5) 
 
0.89 [0.74,1.01] 0.69 
 
0.92 [0.8,1.05] 0.25 
2012 
 
128 (46.4) 
 
2536 (47.9) 
 
0.97 [0.85,1.10] 0.54 
 
1.01 [0.9,1.13] 0.80 
2013 
 
135 (48.9) 
 
2691 (50.8) 
 
0.96 [0.85. 1.09] 0.37 
 
0.99 [0.88,1.1] 0.82 
2014 
 
112 (40.6) 
 
2806 (53) 
 
0.77 [0.66,0.89] 0.003 
 
0.78 [0.68,0.89] <0.001 
2015 
 
102 (37) 
 
2825 (53.3) 
 
0.69 [0.59,0.81] <0.001 
 
0.72 [0.61,0.82] <0.001 
2016 
 
99 (35.9) 
 
2901 (54.8) 
 
0.65 [0.56,0.77] <0.001 
 
0.68 [0.58,0.79] <0.001              
Aspergillus spp. 
          
  
Ivacaftor 
 
Non-ivacaftor Unadjusted Prevalence Ratio 
 
Adjusted Prevalence Ratio 
Year 
 
Culture-
positive (%) 
Culture-positive 
(%) 
PR [95% CI] p 
 
PR [95% CI] p 
2011 
 
26 (9.4) 
 
525 (9.9) 
 
0.95 [0.65,1.38] 0.92 
 
0.93 [0.62,1.32] 0.70 
2012 
 
34 (12.3) 
 
733 (13.8) 
 
0.89 [0.65,1.23] 0.53 
 
0.87 [0.62,1.17] 0.38 
2013 
 
33 (12) 
 
888 (16.8) 
 
0.71 [0.51 0.99] 0.04 
 
0.69 [0.49,0.94] 0.03 
2014 
 
32 (11.6) 
 
1055 (19.9) 
 
0.58 [0.42,0.81] <0.001 
 
0.56 [0.4,0.77] <0.001 
2015 
 
31 (11.2) 
 
1042 (19.7) 
 
0.57 [0.41, 0.80] <0.001 
 
0.56 [0.39,0.77] <0.001 
2016 
 
13 (4.7) 
 
897 (16.9) 
 
0.28 [0.16,0.47] <0.001 
 
0.27 [0.15,0.44] <0.001              
S. aureus 
          
  
Ivacaftor 
 
Non-ivacaftor Unadjusted Prevalence Ratio 
 
Adjusted Prevalence Ratio 
Year 
 
Culture-
positive (%) 
Culture-positive 
(%) 
PR [95% CI] p 
 
PR [95% CI] p 
2011 
 
67 (24.3) 
 
1248 (23.6) 
 
1.03 [0.83,1.28] 0.77 
 
1.04 [0.83,1.27] 0.73 
2012 
 
89 (32.2) 
 
1489 (28.1) 
 
1.15 [0.96,1.37] 0.15 
 
1.14 [0.94,1.34] 0.16 
2013 
 
92 (33.3) 
 
1681 (31.7) 
 
1.05 [0.88,1.25] 0.6 
 
1.04 [0.87,1.22] 0.67 
2014 
 
83 (30.1) 
 
1699 (32.1) 
 
0.94 [0.78,1.13] 0.51 
 
0.92 [0.76,1.1] 0.39 
2015 
 
71 (25.7) 
 
1741 (32.9) 
 
0.78 [0.64,0.96] 0.01 
 
0.77 [0.62,0.94] 0.01 
2016 
 
83 (30.1) 
 
1844 (34.8) 
 
0.86 [0.72,1.04] 0.12 
 
0.85 [0.7,1.01] 0.08              
BCC 
            
Year 
 
Ivacaftor 
 
Non-ivacaftor Unadjusted Prevalence Ratio 
 
Adjusted Prevalence Ratio 
Year 
 
Culture-
positive (%) 
Culture-positive 
(%) 
PR [95% CI] p 
 
PR [95% CI] p 
2011 
 
9 (3.3) 
 
172 (3.2) 
 
1.00 [0.52,1.94] 0.99 
 
0.98 [0.47,1.78] 0.96 
2012 
 
10 (3.6) 
 
184 (3.5) 
 
1.04 [0.56,1.95] 0.87 
 
1.02 [0.51,1.8] 0.95 
2013 
 
12 (4.3) 
 
205 (3.9) 
 
1.12 [0.64,1.98] 0.63 
 
1.1 [0.59,1.85] 0.75 
2014 
 
11 (4) 
 
219 (4.1) 
 
0.96 [0.53,1.74] 0.99 
 
0.93 [0.59,1.75] 0.82 
2015 
 
13 (4.7) 
 
227 (4.3) 
 
1.10 [0.64,1.90] 0.76 
 
1.06 [0.59,1.75] 0.82 
2016 
 
14 (5.1) 
 
233 (4.4) 
 
1.15 [0.68,1.95] 0.55 
 
1.11 [0.62,1.8] 0.70 
  517	
 Clearance of P. aeruginosa      
    No   Yes p 
n  54  33  
Age, years  29.0 (8.3)   25.1 (8.8) 0.03 
Male      30 (55.6)   16 (48.5) 0.68 
CFRD      16 (29.6)   5 (15.2) 0.20 
Pancreatic enzymes  50 (92.6)  31 (93.9) 0.99 
FEV1, %predicted     70.3 (27.7)  77.0 (21.9) 0.24 
FEV1, litres    2.5 (1.1)    2.7 (0.9) 0.54 
Annual IV days   19.0 (25.5)  14.8 (22.3) 0.44 
Sweat Chloride, mmol/L      
Pre-ivacaftor  107.4 (11.1)  103.7 (14.1) 0.47 
6-8 weeks post-ivacaftor   58.2 (21.7)  39.8 (17.4) 0.03 
Change    49.2 (16.9)    63.9 (11.7) 0.02 
 518	
CFRD=Cystic fibrosis related diabetes. FEV1=Forced expiratory volume in 1 second. 519	
  520	
Table 4: Clinical characteristics of individuals without documented growth of P. 521	
aeruginosa in the two years prior to initiating ivacaftor with comparison based 522	
upon subsequent acquisition. Data are presented as mean (SD) or count (%). 523	
 524	
 Acquisition of P. aeruginosa      
                            No   Yes p 
n                         85  49  
Age, years           17.1 (9.5)  18.9 (11.1) 0.31 
Male               54 (58.7)  28 (49.1) 0.33 
CFRD              11  (12.0)  8 (14.0) 0.91 
Pancreatic enzymes           78 (84.8)  53 (93.0) 0.22 
FEV1, % predicted        90.1 (18.1)  80.9 (20.4) 0.005 
FEV1 (L)        2.5 (1.1)   2.3 (1.0) 0.28 
Annual IV days         9.3 (19.6)  14.8 (20.4) 0.10 
Sweat Chloride mmol/L      
Pre-ivacaftor      98.4 (30.3)  94.5 (21.6) 0.62 
6-8 weeks post-ivacaftor     53.3 (18.1)  49.8 (17.1) 0.50 
Change   47.1 (19.7)   43.8 (21.2) 0.58 
 525	
CFRD=Cystic fibrosis related diabetes. FEV1=Forced expiratory volume in 1 second. 526	
 527	
 528	
 529	
